Neuronetics, Inc. Files 8-K Report
Ticker: STIM · Form: 8-K · Filed: Jun 6, 2024 · CIK: 1227636
| Field | Detail |
|---|---|
| Company | Neuronetics, Inc. (STIM) |
| Form Type | 8-K |
| Filed Date | Jun 6, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, financials
TL;DR
Neuronetics filed an 8-K today, check for Reg FD and financial updates.
AI Summary
On June 6, 2024, Neuronetics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. The company is incorporated in Delaware and headquartered in Malvern, PA.
Why It Matters
This 8-K filing indicates that Neuronetics, Inc. is providing updated information to the SEC, which could include material disclosures relevant to investors.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain any immediate negative news or significant financial events.
Key Numbers
- 001-38546 — Commission File Number (SEC Filing Identifier)
- 33-1051425 — I.R.S. Employer Identification No. (Tax Identification)
Key Players & Entities
- Neuronetics, Inc. (company) — Registrant
- June 6, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Malvern, PA (location) — Principal Executive Offices
- 3222 Phoenixville Pike (address) — Principal Executive Offices Street
FAQ
What specific information is being disclosed under Regulation FD?
The filing indicates a Regulation FD Disclosure, but the specific details of the disclosure are not provided in the provided text snippet.
What types of financial statements and exhibits are included?
The filing mentions 'Financial Statements and Exhibits' as an item information, but the specific content of these documents is not detailed in the provided text.
When was Neuronetics, Inc. incorporated?
The filing states that the company's jurisdiction of incorporation is Delaware, but does not provide the specific incorporation date.
What is the company's primary business activity?
The company's Standard Industrial Classification is 'SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]', indicating its primary business is in this sector.
What is the contact phone number for Neuronetics, Inc.?
The registrant's telephone number, including area code, is (610) 640-4202.
Filing Stats: 1,054 words · 4 min read · ~4 pages · Grade level 13.1 · Accepted 2024-06-06 06:05:05
Key Financial Figures
- $0.01 — ange on which registered Common Stock ($0.01 par value) STIM The Nasdaq Global M
Filing Documents
- d845750d8k.htm (8-K) — 27KB
- d845750dex991.htm (EX-99.1) — 15KB
- g845750ex99_1p10g1.jpg (GRAPHIC) — 170KB
- g845750ex99_1p11g1.jpg (GRAPHIC) — 196KB
- g845750ex99_1p12g1.jpg (GRAPHIC) — 52KB
- g845750ex99_1p13g1.jpg (GRAPHIC) — 327KB
- g845750ex99_1p14g1.jpg (GRAPHIC) — 307KB
- g845750ex99_1p15g1.jpg (GRAPHIC) — 418KB
- g845750ex99_1p16g1.jpg (GRAPHIC) — 54KB
- g845750ex99_1p17g1.jpg (GRAPHIC) — 178KB
- g845750ex99_1p18g1.jpg (GRAPHIC) — 316KB
- g845750ex99_1p1g1.jpg (GRAPHIC) — 180KB
- g845750ex99_1p2g1.jpg (GRAPHIC) — 688KB
- g845750ex99_1p3g1.jpg (GRAPHIC) — 97KB
- g845750ex99_1p4g1.jpg (GRAPHIC) — 133KB
- g845750ex99_1p5g1.jpg (GRAPHIC) — 176KB
- g845750ex99_1p6g1.jpg (GRAPHIC) — 272KB
- g845750ex99_1p7g1.jpg (GRAPHIC) — 219KB
- g845750ex99_1p8g1.jpg (GRAPHIC) — 252KB
- g845750ex99_1p9g1.jpg (GRAPHIC) — 174KB
- 0001193125-24-155511.txt ( ) — 5964KB
- stim-20240606.xsd (EX-101.SCH) — 3KB
- stim-20240606_lab.xml (EX-101.LAB) — 17KB
- stim-20240606_pre.xml (EX-101.PRE) — 11KB
- d845750d8k_htm.xml (XML) — 3KB
Forward-Looking Statements
Forward-Looking Statements This Form 8-K contains forward-looking statements within the federal securities laws. These forward-looking statements may be identified by terms such as "outlook," "potential," "believe," "expect," "plan," "anticipate," "predict," "may," "will," "could," "would" and "should" as well as the negative of these terms and similar expressions. These statements include those relating to the Company's business outlook and current expectations for upcoming quarters and fiscal year 2024, including with respect to revenue, expenses, growth, and any statements of assumptions underlying any of the foregoing items. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this release. These risks and uncertainties include, without limitation, risks and uncertainties related to: the Company's ability to execute its business strategy; the Company's ability to achieve or sustain profitable operations due to its history of losses; the Company's reliance on the sale and use of its NeuroStar Advanced Therapy system to generate revenues; the scale and efficacy of the Company's salesforce; the Company's ability to retain talent; availability of coverage and reimbursement from third-party payors for treatments using the Company's products; physician and patient demand for treatments using the Company's products; developments in competing technologies and therapies for the indications that the Company's products treat; product defects; revenue concentration among a small number of customers; the Company's ability to obtain and maintain intellectual property protection for its technology; developments in clinical trials or regulatory review of NeuroStar Advanced Therapy system for additional indications; developments in regulation in the U.S. and other applicable jurisdictions; the